AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights

AstraZeneca's Phase 3 trial for a rare disease (HSCT-TMA) failed, impacting its competitive position.

H.C. Wainwright reiterated a 'Buy' rating on Omeros, citing improved prospects for its drug Yartemlea.

The analyst views AstraZeneca's setback as a 'clear positive' for Omeros's Yartemlea in the same indication.

Yartemlea is an Omeros drug targeting HSCT-TMA, a rare disease with limited treatment options.